TELA
TELA Bio, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.97
−0.48%Oct 5, 2026, 12:00 UTC
The U.S. Food and Drug Administration granted 510(k) clearance to TELA Bio's Liora Monofilament Scaffold for soft tissue reinforcement.
Source:Sep 29, 2026, 20:14 UTC
TELA Bio, Inc. obtained a limited consent from Perceptive Credit Holdings V, LP and the consenting lenders waiving the minimum revenue covenant under its credit agreement for the fiscal quarters ending on or about September 30, 2026 and December 31, 2026.
Aug 31, 2026, 11:11 UTC
Heather Getz was appointed principal financial officer of TELA Bio, Inc., effective August 31, 2026.
Aug 31, 2026, 11:00 UTC
TELA Bio announced a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million or 18%.
Source:Aug 31, 2026, 11:00 UTC
TELA Bio announced a transition in its Chief Operating Officer and Chief Financial Officer roles.
Source:Aug 13, 2026, 00:00 UTC
TELA Bio, Inc. announced the departure of Chief Executive Officer Antony Koblish, effective August 3, 2026, with severance and equity acceleration terms disclosed in an 8-K filing.
Aug 10, 2026, 22:56 UTC
TELA Bio, Inc. reported a second-quarter loss of $0.20 per share, missing the Zacks Consensus Estimate of a $0.17 loss, and compared to a $0.22 loss a year earlier.
Source:Aug 4, 2026, 11:00 UTC
TELA Bio announced the appointment of Heather Getz as Chief Executive Officer and Director, effective August 4, 2026.